Table 2.
Cardiovascular risks scores and inflammatory biomarkers in 181 male patients according to elevated biomarkers.
| Variables | At least one elevated biomarker | P value | ||
|---|---|---|---|---|
| Yes (n = 130) | No (n = 51) | Total (n = 181) | ||
| DAD 5-year CHD score (median: Q1, Q3) | 3.8 (2.4, 7.6) | 2.7 (1.1, 5.8) | 3.6 (2.0, 7.2) | 0.005 |
| DAD 5-year CVD score (median: Q1, Q3) | 4.6 (3.0, 9.1) | 3.5 (1.5, 7.3) | 4.4 (2.5, 8.4) | 0.009 |
| Framingham 10-year CVD score (median: Q1, Q3) | 12.0 (6.5, 19.8) | 7.2 (3.8, 16.6) | 10.8 (5.7, 19.2) | 0.003 |
| Framingham 10-year CVD score > 20% (n,%) | 32 (24.6) | 10 (19.6) | 42 (23.2) | 0.473 |
| CD40L, pg/ml (median: Q1, Q3) | 1132 (554, 2196) | 846.8 (578, 1147) | 933.6 (554, 1862) | 0.004 |
| MCP-1 pg/ml (median: Q1, Q3) | 583.0 (459, 737) | 449.8 (398, 512) | 527.7 (428, 672) | <0.001 |
| IL-8, pg/ml (median: Q1, Q3) | 7.2 (3.0, 14.3) | 2.6 (0.0, 8.6) | 6.1 (1.5, 11.1) | <0.001 |
| IL-6, pg/ml (median: Q1, Q3) | 3.4 (1.2, 6.5) | 0.9 (0.0, 3.0) | 2.4 (0.6, 5.0) | <0.001 |
| hCRP mg/L (median: Q1, Q3) | 2.2 (1.0, 5.7) | 1.0 (0.6,1.8) | 1.8 (0.8, 4.2) | <0.001 |
| P-selectin, ng/ml (median: Q1, Q3) | 203.23 (162, 269) | 183.6 (130, 216) | 200.1 (156, 256) | 0.014 |
| Carotid intima media thickness, mm (median: Q1, Q3) | 0.7 (0.6, 0.8) | 0.6 (0.5, 0.8) | 0.7 (0.6, 0.8) | 0.061 |
| Inflammatory burden score (n, %) | ||||
| 0 | 51 (28.2) | 51 (28.2) | ||
| 1 | 45 (24.9) | 45 (24.9) | ||
| 2 | 48 (26.5) | 48 (26.5) | ||
| 3 | 20 (11.0) | 20 (11.0) | ||
| 4 | 11 (6.1) | 11 (6.1) | ||
| 5 | 6 (3.3) | 6 (3.3) | ||
DAD, Data collection on Adverse effects of anti-HIV Drugs study; CHD, coronary haert disease; CVD, cardiovascular disease; IL, interleukin; MCP, monocyte chemoattractant protein; hCRP, high sensitivity C-reactive protein; Q1, first quartile; Q3, third quartile.